利福平浓度不足与结核治疗不良结局相关
在印度接受每周三次方案的新发肺结核患者前瞻性队列中,第1个月利福平、异烟肼和吡嗪酰胺浓度低于治疗阈值者分别占85%、29%和13%。利福平浓度每降低1 µg/mL与不良结局独立相关(aIRR 1.21,95%CI 1.01-1.47)及治疗失败相关(aIRR 1.16,95%CI 1.05-1.28);吡嗪酰胺浓度每降低1 µg/mL与复发相关(aIRR 1.05,95%CI 1.01-1.11)。
要点
- 每周三次方案下多数患者利福平浓度低于8 µg/mL。
- 利福平浓度降低与不良结局和治疗失败独立相关。
- 吡嗪酰胺浓度降低与复发相关。
核心结论
- 印度每周三次结核方案中利福平浓度普遍低于治疗阈值,低利福平和吡嗪酰胺浓度与不良结局相关。
研究设计与样本
- 前瞻性队列纳入404例印度新发肺结核患者,接受每周三次治疗,于第1和第5个月给药后2小时采血测最大血药浓度。
主要发现
- 第1个月利福平、异烟肼和吡嗪酰胺浓度低于治疗阈值者分别占85%、29%和13%。
- 不良结局发生率为19%。
- 利福平浓度每降低1 µg/mL与不良结局独立相关(aIRR 1.21,95%CI 1.01-1.47)及治疗失败相关(aIRR 1.16,95%CI 1.05-1.28)。
- 吡嗪酰胺浓度每降低1 µg/mL与复发相关(aIRR 1.05,95%CI 1.01-1.11)。
关键数值与推荐
- 利福平亚治疗阈值定义为<8 µg/mL。
- 异烟肼亚治疗阈值定义为<3 µg/mL。
- 吡嗪酰胺亚治疗阈值定义为<20 µg/mL。
临床怎么用
- 对每周三次结核方案患者应关注利福平血药浓度,低浓度提示不良结局风险。
- HIV合并感染者利福平浓度可能更低,需加强监测。
- 印度每周三次方案可能需要更高或更频繁给药以改善结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The relationships between first-line drug concentrations and clinically important outcomes among patients with tuberculosis (TB) remain poorly understood. METHODS: We enrolled a prospective cohort of patients with new pulmonary TB receiving thrice-weekly treatment in India. The maximum plasma concentration of each drug was determined at months 1 and 5 using blood samples drawn 2 hours postdose. Subtherapeutic cutoffs were: rifampicin <8 µg/mL, isoniazid <3 µg/mL, and pyrazinamide <20 µg/mL. Factors associated with lower log-transformed drug concentrations, unfavorable outcomes (composite of treatment failure, all-cause mortality, and recurrence), and individual outcomes were examined using Poisson regression models. RESULTS: Among 404 participants, rifampicin, isoniazid, and pyrazinamide concentrations were subtherapeutic in 85%, 29%, and 13%, respectively, at month 1 (with similar results for rifampicin and isoniazid at month 5). Rifampicin concentrations were lower with human immunodeficiency virus coinfection (median, 1.6 vs 4.6 µg/mL; P = .015). Unfavorable outcome was observed in 19%; a 1-μg/mL decrease in rifampicin concentration was independently associated with unfavorable outcome (adjusted incidence rate ratio [aIRR], 1.21 [95% confidence interval {CI}, 1.01-1.47]) and treatment failure (aIRR, 1.16 [95% CI, 1.05-1.28]). A 1-μg/mL decrease in pyrazinamide concentration was associated with recurrence (aIRR, 1.05 [95% CI, 1.01-1.11]). CONCLUSIONS: Rifampicin concentrations were subtherapeutic in most Indian patients taking a thrice-weekly TB regimen, and low rifampicin and pyrazinamide concentrations were associated with poor outcomes. Higher or more frequent dosing is needed to improve TB treatment outcomes in India.
引用
- Ramachandran G, Chandrasekaran P, Gaikwad S, et al. Subtherapeutic Rifampicin Concentration Is Associated With Unfavorable Tuberculosis Treatment Outcomes. Clin Infect Dis. 2020. PMID: 31075166. doi:10.1093/cid/ciz380
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。